

From: Liverpool-ECMC
Sent: 24 June 2019 10:49
To: Liverpool-ECMC
Subject: Liverpool ECMC Newsletter June 2019

LIVERPOOL ECMC NEWSLETTER JUNE 2019

[Who are the Liverpool ECMC team? Find out here...](#)

UPDATES FROM THE LIVERPOOL ECMC

Welcome to the first Liverpool ECMC monthly newsletter. We hope to keep you up to date with ongoing work in the Liverpool ECMC including:

- Open and upcoming trials
- News from the Liverpool ECMC
- Events and training opportunities
- Job opportunities and involvement with national initiatives.



ECMC ANNUAL NETWORK MEETING

Members of the Liverpool ECMC team attended the ECMC Annual Network Meeting in London on Thursday 23rd May.

The meeting focused on three key areas; reverse translation capabilities, innovation in clinical trial operations and delivery of complex trials.

It was a great opportunity for members of the team from CCC, the LCTU and GCPLab to network with colleagues at other centres.

All ECMCs provided posters to exhibit their achievements over the last reporting year. The Liverpool ECMC showcased the advances made in the development of digital immunohistochemistry approaches, overcoming challenges in toxicity based sampling and translational work leading to a biomarker-based trial of combination therapies in pancreatic cancer.



ECMC NETWORK GROUPS

The ECMC Network Groups bring together expertise from across the national ECMC centres and provides the ECMC research community with a forum for peer-to-peer support, training and development, improving quality and standards, and tackling particular research challenges in early phase and translational research.

If you would be keen to get involved in any of the following please contact livecmc@liv.ac.uk:

- **Research Nurses Network Group**
- **Quality Assurance and Translational Science (QATS) Network Group**
- **Junior Investigator Network Group (JING)**
- **UK Therapeutic Cancer Prevention Network Group (UKTCPN)**
- **CRUK, ECMC and UK Radiopharmacy Group Taskforce (CERT)**
- **Cellular and Molecular Pathology (CMP) Network Group**



NEW TRIALS OPENING

- **POLARIS** - Phase 1-2 Study of ADI-PEG 20 plus FOLFOX in Subjects with Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma - *Hepatocellular Carcinoma*

[Find out more...](#)

OPEN TRIALS / SLOTS

Please contact **Jennie Derham** for potential referral to these trials.

- Telephone: 0151 556 5443
- Mobile: 07554 416 293



- **ACIT-1** – A Phase I clinical study to determine the optimal dose for the safe immune restoration and immune response of allogeneic cell immunotherapy (ACIT-1) in adult cancer patients – *All advanced solid tumours.*
- **REPLIMUNE RP1** – An Open-Label, Multicenter, Phase 1/2 Study of RPI as a Single Agent and in Combination with Immune Checkpoint Blockade or Other Standard of Care Regimens in Patients with Solid Tumors – *Soft tissue sarcoma, stage III-IV melanoma, triple negative breast cancer, non-small cell lung cancer and non-melanoma skin cancer.*
- **BGB-290-106** – An Open-Label, Multicenter, Phase 1/2 Study of RPI as a Single Agent and in Combination with Immune Checkpoint Blockade or Other Standard of Care Regimens in Patients with Solid Tumors – *Soft tissue sarcoma, stage III-IV melanoma, triple negative breast cancer, non-small cell lung cancer and non-melanoma skin cancer.*
- **plasmaMATCH** – A multiple parallel cohort, non-randomised, open label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening – *Advanced breast cancer.*
- **BLU 554** – A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients with Hepatocellular Carcinoma and Cholangiocarcinoma – *Hepatocellular carcinoma and cholangiocarcinoma.*

- **OUTREACH** – A First-in-Human, multi-centre, open-label, Phase 1 clinical study with RNA oligonucleotide drug MTL-CEBPA to investigate its safety and tolerability in patients with advanced liver cancer (OUTREACH) – *Advanced liver cancer*.
- **Cambridge Brain Mets Trial 1** – A proof of principle phase 1b / randomised phase 2 study of afatinib penetration into cerebral metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy – *Brain metastases from lung or breast primary*.
- **WISTERIA** - A Phase I trial of WEE1 inhibition with Chemotherapy and Radiotherapy as adjuvant treatment, and a Window of Opportunity trial with Cisplatin in Patients with Head and Neck Cancer – *Oral, laryngeal or hypopharyngeal squamous cell carcinoma*.

Find out more...

EVENTS & JOB OPPORTUNITIES

EVENTS

- **Conference: Phase 1 where science becomes medicine**
- **New directions in Immuno-Oncology**
- **<https://www.ecmcnetwork.org.uk/events>**

CONTACT US

If you require any information which isn't on the website please contact the Liverpool ECMC Team via **e-mail**.

Copyright © 2019 Liverpool ECMC, All rights reserved.

Our mailing address is:

livecmc@liv.ac.uk